
New Zealand approves MDMA for PTSD treatment in controlled clinical settings
The story in brief
New Zealand has approved MDMA-assisted treatment for severe PTSD, combining it with psychotherapy in controlled settings. The country is the second globally to do so, following Australia. Clinical trials continue in the U.S., where the FDA rejected MDMA's medicinal use in 2024 due to insufficient evidence.